TABLE 2.
Small molecules and novel preparations targeting glycolysis in NSCLC.
| No. | Drug name | Target | Publication year | Category | DOI |
|---|---|---|---|---|---|
| 1 | Caudatin | Raf/MEK/ERK pathway | 2022 | Chemical molecular | 10.1080/13880209.2022.2050768 |
| 2 | Crizotinib | Anaplastic lymphoma kinase (ALK) inhibitor | 2021 | Chemical molecular | 10.1111/1759-7714.14184 |
| 3 | Gefitinib | EGFR | 2020 | Chemical molecular | 10.12122/j.issn.1673-4254.2020.06.17 |
| 4 | Dichloroacetate (DCA) | HIF-3α | 2020 | Chemical molecular | 10.1155/2020/3176375 |
| 5 | Fenbendazole | Acetylcholinesterase (AChE) | 2018 | Chemical molecular | 10.1038/s41598-018-30158-6 |
| 6 | Albendazole | HIF-1α/VEGF | 2017 | Chemical molecular | 10.1007/s11010-016-2927-3 |
| 7 | Gal-Pt | GLUTs | 2016 | Chemical molecular conjugate | 10.1016/j.ejmech. 2016.01.016 |
| 8 | Ad-apoptin | AMPK/mTOR signaling pathway | 2021 | Oncolytic adenovirus | 10.1016/j.yexcr. 2021.112926 |
| 9 | siRNA and DTX | Phosphoglycerate mutase 1 (PGAM1) | 2021 | Nanovesicle | 10.1186/s12951-021-01085-y |